Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders

Neuron. 2017 May 3;94(3):431-446. doi: 10.1016/j.neuron.2017.03.016.

Abstract

G-protein-coupled receptors (GPCRs) play critical roles in regulating brain function. Recent advances have greatly expanded our understanding of these receptors as complex signaling machines that can adopt numerous conformations and modulate multiple downstream signaling pathways. While agonists and antagonists have traditionally been pursued to target GPCRs, allosteric modulators provide several mechanistic advantages, including the ability to distinguish between closely related receptor subtypes. Recently, the discovery of allosteric ligands that confer bias and modulate some, but not all, of a given receptor's downstream signaling pathways can provide pharmacological modulation of brain circuitry with remarkable precision. In addition, allosteric modulators with unprecedented specificity have been developed that can differentiate between subpopulations of a given receptor subtype based on the receptor's dimerization state. These advances are not only providing insight into the biological roles of specific receptor populations, but hold great promise for treating numerous CNS disorders.

Keywords: GPCR; NAM; PAM; allosteric modulator; dopamine receptor; mAChR; mGlu; metabotropic glutamate receptor; muscarinic receptor; schizophrenia.

Publication types

  • Review

MeSH terms

  • Allosteric Regulation / drug effects*
  • Animals
  • Antipsychotic Agents / pharmacology*
  • Antipsychotic Agents / therapeutic use
  • Central Nervous System Diseases / drug therapy
  • Cognition / drug effects
  • Humans
  • Prefrontal Cortex / drug effects
  • Receptor, Metabotropic Glutamate 5 / drug effects
  • Receptor, Muscarinic M4 / drug effects
  • Receptors, Dopamine / drug effects*
  • Receptors, G-Protein-Coupled / drug effects
  • Receptors, Metabotropic Glutamate / drug effects*
  • Receptors, Muscarinic / drug effects*
  • Schizophrenia / drug therapy*

Substances

  • Antipsychotic Agents
  • Receptor, Metabotropic Glutamate 5
  • Receptor, Muscarinic M4
  • Receptors, Dopamine
  • Receptors, G-Protein-Coupled
  • Receptors, Metabotropic Glutamate
  • Receptors, Muscarinic
  • metabotropic glutamate receptor type 1